Cisplatin is an inorganic platinum complex that inhibits DNA synthesis by forming DNA crosslinking agents, inactivates GPXs, reduces cell GSH and induces iron death in HCT116 and A549 cells.
DMSO can inactivate Cisplatin's activity!
Sci Rep. 2022 Oct 17;12(1):17358.
Screening of the siGPCR library in combination with cisplatin against lung cancers
Cisplatin purchased from AbMole
Phytochemistry. 2022 Dec 12;207:113558.
Diverse alkaloids from the aerial parts of Aconitum carmichaelii and antiproliferative activity of costemline via inhibiting SIRT1/ROCK1/P-STAT3 pathways
Cisplatin purchased from AbMole
J Immunother Cancer. 2022 Oct;10(10):e005270.
CUL3/SPOP complex prevents immune escape and enhances chemotherapy sensitivity of ovarian cancer cells through degradation of PD-L1 protein
Cisplatin purchased from AbMole
Evid Based Complement Alternat Med. 2022 Apr 6;2022:4445293.
Zhenzhu Xiaoji Decoction Induces Autophagy and Apoptosis Cell Death in Liver Cancer Cells through AKT/mTOR and JAK2/STAT3 Signaling Pathway
Cisplatin purchased from AbMole
Clin Epigenetics. 2021 Jul 22;13(1):142.
Genome-wide DNA methylome analysis identifies methylation signatures associated with survival and drug resistance of ovarian cancers
Cisplatin purchased from AbMole
Bioengineered. 2021 Dec;12(1):2499-2510.
Targeting the miR-6734-3p/ZEB2 axis hampers development of non-small cell lung cancer (NSCLC) and increases susceptibility of cancer cells to cisplatin treatment
Cisplatin purchased from AbMole
2020 Dec.
A Novel Circular RNA hsa_circRNA_103809/miR-377-3p/GOT1 Pathway Regulates Cisplatin-Resistance in Non-Small Cell Lung Cancer (NSCLC)
Cisplatin purchased from AbMole
Open Life Sciences. 2020 June;15(1):409-417.
Buformin suppresses osteosarcoma via targeting AMPK signaling pathway
Cisplatin purchased from AbMole
Aging (Albany NY). 2020 Jun 9;12(11):11025-11041.
LncRNA ADAMTS9-AS2 inhibits gastric cancer (GC) development and sensitizes chemoresistant GC cells to cisplatin by regulating miR-223-3p/NLRP3 axis
Cisplatin purchased from AbMole
Cell Cycle. 2018;17(10):1235-1244.
Apatinib, a novel tyrosine kinase inhibitor, suppresses tumor growth in cervical cancer and synergizes with Paclitaxel.
Cisplatin purchased from AbMole
Cancer Biol Ther. 2018 Feb 5.
Buformin suppresses proliferation and invasion via AMPK/S6 pathway in cervical cancer and synergizes with paclitaxel
Cisplatin purchased from AbMole
J Korean Med Sci. 2016 Jun;31(6): 836–842.
Silencing of ABCG2 by MicroRNA-3163 Inhibits Multidrug Resistance in Retinoblastoma Cancer Stem Cells
Cisplatin purchased from AbMole
Cell Experiment | |
---|---|
Cell lines | A549-luc cell |
Preparation method | Cells were allowed to adhere for 24 hours and subsequently incubated with either PRINT-Platin or cisplatin at concentrations ranging from 9.8 nM to 80 µM (drug concentration) for 72 hours at 37 °C in a humidified 5 % CO2 atmosphere. After the incubation period, all media/particles were aspirated off cells. 100 µL fresh medium was added back to cells, followed by the addition of 100 µL CellTiter-Glo® Luminescent Cell Viability Assay reagent. |
Concentrations | 9.8 nM to 80 µM |
Incubation time | 72 h |
Animal Experiment | |
---|---|
Animal models | healthy mice |
Formulation | pH-adjusted 0.9 wt% NaCl solution |
Dosages | 3 mg/kg |
Administration | vein injection |
Molecular Weight | 300.05 |
Formula | Cl2H6N2Pt |
CAS Number | 15663-27-1 |
Solubility (25°C) | DMF: 6 mg/mL (Need ultrasonic) |
Storage | 2-8°C, protect from light |
Species | Mouse | Rat | Rabbit | Guinea pig | Hamster | Dog |
Weight (kg) | 0.02 | 0.15 | 1.8 | 0.4 | 0.08 | 10 |
Body Surface Area (m2) | 0.007 | 0.025 | 0.15 | 0.05 | 0.02 | 0.5 |
Km factor | 3 | 6 | 12 | 8 | 5 | 20 |
Animal A (mg/kg) = Animal B (mg/kg) multiplied by | Animal B Km |
Animal A Km |
For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.
Related DNA/RNA Synthesis Products |
---|
D-I03
D-I03 is a selective RAD52 inhibitor with a Kd of 25.8 µM. D-I03 specifically inhibits RAD52-dependent single-strand annealing (SSA) and D-loop formation with IC50s of 5 µM and 8 µM, respectively. |
Bractoppin
Bractoppin is a potent and selective inhibitor of phosphopeptide recognition by the human BRCA1 tandem(t) BRCT domain with IC50 of 74 nM. Bractoppin diminishes BRCA1 recruitment to DNA breaks, in turn suppressing damage-induced G2 arrest and assembly of the recombinase, RAD51. |
Plitidepsin
Plitidepsin (Aplidine) is a potent anticancer compound targeting eEF1A2 (KD=80 nM). Plitidepsin has antiviral activity, and the IC90 of inhibiting SARS-CoV-2 is 0.88 nM. Plitidepsin is commonly used in multiple myeloma and advanced cancer research and has potential for COVID-19 research. |
Tofersen
Tofersen (BIIB067) is an antisense oligonucleotide that mediates RNase H-dependent degradation of superoxide dismutase 1 (SOD1) mRNA to reduce SOD1 protein synthesis. Tofersen can be used in amyotrophic lateral sclerosis (ALS) research. |
ART812
ART812 is an orally effective DNA polymerase Polθ inhibitor with an IC50 value of 7.6 nM. ART812 had an IC50 value of 240 nM for cell-based microhomologous mediated end-junction (MMEJ). |
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2020 AbMole BioScience. All Rights Reserved.